Interestingly, our data identified RPS4X, RPL34, and VMP1 as having more profound effects than ESR1 for ER+ BC, while the majority of the identified therapeutic targets for HER2+ BC exhibited more potent inhibitory effects than targeting ERBB2 (i.e., RPS29, etc.). Here, RPS29 is linked to breast cancer.